SUPPORTING TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Tiotropium is the drug of first-line supporting treatment of chronic obstructive pulmonary disease (COPD), the efficacy and safety of which is supported by higher level evidence and broad experience of the use in medical practice. Many pharmacoeconomic studies have shown that the clinical benefits of tiotropium compared with placebo and active comparators lead to its economic advantages, primarily by reducing the cost of hospitalization, and allow to consider the tiotropium as a drug of choice for the supporting treatment of COPD.

Full Text

Restricted Access

About the authors

E. A Ushkalova

PFUR

Email: eushk@yandex.ru
MD, Prof. at the Department of Genera! and Clinical Pharmacology

References

  1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-28.
  2. Социально-экономическое бремя бронхиальной астмы и хронической обструктивной болезни легких в Российской Федерации. РРОФ «Качество жизни» НИИ КЭФФ. М., 2009. http://www.mednet.ru/ru/ novosti/1008-2605201 1--bolee-300-mln-paczientov-v-mire-i-900-tysyach-v-rossii--ofic-zialnaya-statistika-zabolevaemosti-bronxialnoj-astmoj.html
  3. Lawrence R.S., Mickalide A.D., Kamerow D.B., Woolf S.H. Report of the US Preventive Services Task Force. JAMA. 1990;263:436-37.
  4. Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-73.
  5. Yawn B.P., Keenan J.M. COPD - the primary care perspective: addressing epidemiology, pathology, diagnosis, treatment of smoking's multiple morbidities and the patient's perspective. COPD. 2007;4(1):67-83.
  6. Teramoto S. COPD pathogenesis from the viewpoint of risk factors.Intern Med. 2007; 46(2):77-9.
  7. Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M., Menezes A.M., Sullivan S.D., Lee T.A., Weiss K.B., Jensen R.L., Marks G.B., Gulsvik A., Nizankowska-Mogilnicka E.; BOLD Collabo-rative Research Group.International variation in the prevalence of COPD (the BOLD Study): a population based prevalence study. Lancet. 2007;370:741-50.
  8. Eisner M.D., Blanc P.D., Yelin E.H., Sidney S., Katz P.P., Ackerson L., Lathon P., Tolstykh I., Omachi T., Byl N., Iribarren C. COPD as a systemic disease: impact on physical functional limitations. Am. J. Med. 2008;121(9): 789-96.
  9. Dal Negro R. W., Bonadiman L., Tognella S., Bricolo F.P., Turco P. Extent and prevalence of cognitive dysfunction in chronic obstructive pulmonary disease, chronic non-obstructive bronchitis, and in asymptomatic smokers, compared to normal reference values. Int. J. Chron. Obstruct Pulmon Dis. 2014;9:675-83.
  10. World Health Organization (2011) Asthma Fact Sheet. Geneva: World Health Organization. Available: http://www.who.int/mediacentre/ factsheets/fs307/en/World Health Organization (2013). Chronic obstructive pulmonary disease (COPD). Available: http://www.who.int/respira-tory/copd/en/
  11. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524): 1747-57.
  12. Chapman K.R., Mannino D.M., Soriano J.B., Vermeire P.A., Buist A.S., Thun M.J., Connell C., Jemal A., Lee T.A., Miravitlles M., Aldington S., Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1):188-207.
  13. Rycroft C.E., Heyes A., Lanza L., Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int. J. Chron. Obstruct Pulmon Dis. 2012;7:457-94.
  14. Aryal S., Diaz-Guzman E., Mannino D.M. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int. J. Chron. Obstruct Pulmon Dis. 2014; 9:1145-54.
  15. Global Initiative for Chronic Obstructive Lung Disease; 2014. Available from: http://www. goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html
  16. National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre; 2010. Available from: http:// guidance.nice.org.uk/CG101/Guidance/pdf/
  17. Criner G.J., Bourbeau J., Diekemper R.L., Ouellette D.R., Goodridge D., Hernandez P., Curren K., Balter M.S., Bhutani M., Camp P.G., Celli B.R., Dechman G., Dransfield M.T., Fiel S.B., Foreman M.G., Hanania N.A., Ireland B.K., Marchetti N., Marciniuk D.D., Mularski R.A., Ornelas J., Road J.D., Stickland M.K. Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2014 Oct 16. [Epub ahead of print]
  18. De Coster D.A., Jones M. Tailoring of corticosteroids in COPD management. Curr. Respir. Care Rep. 2014;3:121-32.
  19. Meyer K. C. COPD 2013: An update on treatment and newly approved medications for pharmacists. J Am Pharm Assoc (2003). 2013;53(6): e219-29.
  20. Yohannes A.M., Willgoss T.G., Vestbo J. Tiotropium for treatment of stable COPD: a metaanalysis of clinically relevant outcomes. Respir. Care 2011,56:477-87.
  21. Incorvaia C., Ridolo E., Riario-Sforza E. Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease: From Clinical Trials to Daily Practice. Rev Recent Clin Trials. 2014 May 30. [Epub ahead of print].
  22. Garjon F.J., Azparren A., Vergara I., Azaola B., Loayssa J.R. Adoption of new drugs by physicians: a survival analysis. BMC Health Serv. Res. 2012;12:56.
  23. Jones M.I., Greenfield S.M., Bradley C.P. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001;323:378-81.
  24. Prosser H., Walley T. New drug uptake: quali tative comparison of high and low prescribing GPs' attitudes and approach. Fam. Pract. 2003; 20:583-91.
  25. Wang J., Jin D., Zuo P., Wang T., Xu Y., Xiong W. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology. 2011;16(2):350-58.
  26. Karner C., Cates C.J. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011;(3):CD008532.
  27. Rodrigo G.J., Plaza V., Castro-Rodriguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol. Ther. 2012; 25(1):40-7.
  28. Karner C., Cates C.J. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(9):CD009039.
  29. Karner C., Cates C.J. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012;4:CD008989.
  30. Qureshi H., Sharafkhaneh A., Hanania N.A. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther. Adv. Chronic Dis. 2014; 5(5):212-27.
  31. Olin J.L. Tiotropium: An Inhaled Anticholinergic for Chronic Obstructive Pulmonary Disease. Am. J. Health Syst. Pharm. 2005;62(12):1263-69.
  32. Restrepo R.D. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care. 2007;52(7):833-51.
  33. Tashkin D.P. Preventing and managing exacerbations in COPD - critical appraisal of the role of tiotropium. Int. J. Chron. Obstruct Pulmon Dis. 2010;5:41-53.
  34. Casaburi R., Maltais F., Porszasz J., Albers F., Deng Q., Iqbal A., Paden H.A., O'Donnell D.E. Effect of Tiotropium on Hyperinflation and Treadmill Exercise Tolerance in Mild-Moderate Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac Soc. 2014 Oct 7. [Epub ahead of print].
  35. Wollin L., Pieper M. Tiotropiumbromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm Pharmacol. Ther. 2010;23:345-54.
  36. Brown S.M., Koarai A., Sturton R.G., Nicholson A.G., Barnes P.J., Donnelly L.E. A role for M(2) and M(3) muscarinic receptors in the contraction of rat and human small airways. Eur. J. Pharmacol. 2013;702:109-15.
  37. Holownia A., Mroz R.M., Skopinski T., Kolodziejczyk A., Chyczewska E., Braszko J.J. Tiotropium increases PPARy and decreases CREB in cells isolated from induced sputum of COPD patients. Adv. Exp. Med. Biol. 2013;756:9-14.
  38. Elder W.G., Munk N. Using the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) Model in Clinical Research: Application to Refine a Practice-based Research Network (PBRN) Study. J. Am. Board Fam. Med. 2014; 27(6):846-54.
  39. Rau-Berger H., Mitfessel H., Glaab T. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct Pulmon Dis. 2010;5:367-73.
  40. Chen A.M., Bollmeier S.G., Finnegan P.M. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann. Pharmacother. 2008;42(12):1832-42.
  41. Barr R.G., Bourbeau J., Camargo C.A, Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006;61(10):854-62.
  42. Halpin D., Menjoge S., Viel K. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim. Care Respir. J. 2009; 18(2):106-13.
  43. Wu Q., Li G., Lei W.I., Zhou X. The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis. Respirology. 2009; 14(5):666-74.
  44. Cooper C.B., Anzueto A., Decramer M., Celli B., Tashkin D.P., Leimer I., Kesten S. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebocontrolled clinical trials. Int. J. Chron. Obstruct Pulmon Dis. 2011;6:269-75.
  45. Anzueto A., Niewoehner D.E., Leimer I., Rühmkorf F., Celli B.R., Decramer M., Tashkin D.P. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Respir. Med. 2013;107(12): 1912-22.
  46. Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014;7:CD009285.
  47. Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013;9:CD009552.
  48. Van den Bruel A., Gailly J., Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a metaanalysis. BMC Pulm Med. 2010;10:50.
  49. Rodrigo G.J., Nannini L.J. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol. Ther. 2007;20(5):495-502.
  50. Chong J., Karner C., Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157.
  51. Salpeter S.R., Buckley N.S. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol. 2006; 31(2-3):219-30.
  52. Celli B., Decramer M., Leimer I., Vogel U., Kesten S., Tashkin D.P. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137( 1 ):20-30.
  53. Mathioudakis A.G., Kanavidis P., Chatzimavridou-Grigoriadou V., Gialmanidis I.P., Amanetopoulou S.G., Christopoulou E., Evangelopoulou E., Mathioudakis G.A. Tiotropium HandiHaler improves the survival of patients with COPD: a systematic review and meta-analysis. J. Aerosol Med. Pulm. Drug Deliv. 2014;27(1):43-50.
  54. De Luise C., Lanes S.F., Jacobsen J., Pedersen L., Sorensen H.T. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur. J. Epidemiol. 2007;22:267-72.
  55. Gershon A.S., Wang L., To T., Luo J., Upshur R.E. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease. COPD. 2008;5(4):229-34.
  56. Tashkin D.P., Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008;359:1543-54.
  57. Troosters T., Celli B., Lystig T., Kesten S., Mehra S., Tashkin D.P., Decramer M.; Uplift Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur. Respir. J. 2010;36:65-73.
  58. Morice A.H., Celli B., Kesten S., Lystig T., Tashkin D., Decramer M. COPD in young patients: A pre specified analysis of the four-year trial of tiotropium (UPLIFT). Respir. Med. 2010;104:1659-67.
  59. Decramer M., Celli B., Kesten S., L Lystig T., Mehra S., Tashkin D.P. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171-78.
  60. Tashkin D.P. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med. 2010;16(2):97-105.
  61. Kaplan A. Effect of tiotropium on quality of life in COPD: a systematic review. Prim. Care Respir. J. 2010;19(4):315-25.
  62. Cooper C.B., Celli B.R., Jardim J.R., Wise R.A., Legg D., Guo J., Kesten S. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest. 2013;144(2):490-97.
  63. Santus P., Di Marco F., Radovanovic D., Centanni S.Tiotropium: what came after the UPLIFT study. Expert Opin Pharmacother. 2012; 13(4):613-18.
  64. Baker W.L., Baker E.L., Coleman C.I. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009;29(8):891-905.
  65. Welsh E.J., Cates C.J., Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;(5):CD007891.
  66. Cope S., Donohue J.F., Jansen J.P., Kraemer M., Capkun-Niggli G., Baldwin M., Buckley F., Ellis A., Jones P. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013;14:100.
  67. Chapman K.R., Beeh K.M., Beier J., Bateman E.D. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.
  68. Karabis A., Lindner L., Mocarski M., Huisman E., Greening A. Comparative efficacy of aclidi nium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int. J. Chron Obstruct Pulmon Dis. 2013;8:405-23.
  69. Cope S., Zhang J., Williams J., Jansen J.P. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm. Med. 2012;12:29.
  70. Alexander G.C., O'Connor A.B., Stafford R.S. Enhancing prescription drug innovation and adoption. Ann. Intern. Med. 2011;154(12):833-37, W-301.
  71. Yohannes A.M., Connolly M.J., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron Obstruct Pulmon Dis. 2013;8:117-25.
  72. Keam S.J., Keating G.M. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68.
  73. Keating G.M., Yohannes A.M., Connolly M.J., Hanania N.A. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72(2):273-300.
  74. Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc. 2007; 82(5):575-82.
  75. Mauskopf J.A., Baker C.L., Monz B.U., Juniper M.D. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J. Med. Econ. 2010;13(3):403-17.
  76. Rutten-van Mölken M.P., Goossens L.M. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012; 30(4):271-302.
  77. Архипов В.В. Фармакоэкономический подход к терапии хронической обструктивной болезни легких. Consilium medicum. 2010;3:85-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies